ARA-290: Can It Repair Small Nerve Fibers?
Summary
Host John Garrett examines ARA 290 (sabinatide), an investigational peptide derived from erythropoietin designed to promote tissue repair without stimulating red blood cell production. He reviews early clinical trials in sarcoidosis and diabetic small fiber neuropathy, highlighting promising but inconclusive data on nerve regeneration and symptom relief. The episode emphasizes that while the biological mechanism is plausible, ARA 290 remains unapproved, with limited long-term safety data and significant gaps between preliminary signals and proven clinical efficacy.
Topics discussed
Sponsors: LinkedIn Hiring Pro and Red Bull
Podcast growth and affiliate disclosure update
Introduction to ARA290 and its potential
Welcome to Peptides Explained and disclaimer
Mechanism of action: EPO derivative and IRR
60-second mechanism summary
Small fiber neuropathy symptoms and causes
Early human trials in sarcoidosis patients
Phase 2b study: Corneal nerve fiber data
Trials in diabetic neuropathy and limitations
Evidence ladder and safety unknowns
Online claims vs. actual scientific data
Medical advice: Diagnosis before peptides
Sponsor: Peptide Solutions
Conclusion: ARA290 is investigational, not proven
Sponsors: Nesquik and Uber Eats
Listen ad-free on Castria